睿知中国医院研究地图
候选清单

正在招募淋巴瘤I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 13 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 13

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心安徽省肿瘤医院Anhui Provincial Cancer Hospital合肥医院页面
  2. 研究中心西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面
  3. 研究中心广东省人民医院Guangdong Provincial People's Hospital广州医院页面
  4. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  5. 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
  6. 研究中心临沂市肿瘤医院Linyi Cancer Hospital临沂医院页面
  7. 研究中心北京大学第三医院Peking University Third Hospital北京医院页面
  8. 研究中心浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面
  9. 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面
  10. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
  11. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
  12. 研究中心四川大学华西医院West China Hospital成都医院页面
  13. 研究中心南方医科大学珠江医院Zhujiang Hospital广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07059650,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Patients with pathologically confirmed DLBCL who have not received prior anti-lymphoma therapy.

    入选标准第 2 条

  3. ECOG status score of 0 to 2.

    入选标准第 13 条

  4. Presence of at least one radiologically measurable lesion in 2 perpendicular directions as assessed by CT or MRI and a positive lesion on PET/CT scan consistent with a tumor site identified by CT or MRI.

    入选标准第 14 条

  5. The patient has been diagnosed with other malignant diseases other than B-cell lymphoma within the past 2 years.

    排除标准第 11 条

  6. Women who are pregnant or breastfeeding.

    排除标准第 15 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07059650,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Cohort 1:
  2. Patients with pathologically confirmed DLBCL who have not received prior anti-lymphoma therapy.
  3. Disease stage II to IV by Ann Arbor Classification.
  4. Life expectancy ≥ 12 months.
  5. Cohort 2, 3:
  6. Pathologically confirmed DLBCL patients who have received adequate first-line treatment containing CD20 monoclonal antibody and anthracyclines (such as R-CHOP-like regimen).
  7. Relapsed or refractory to first-line R-CHOP-like regimen.
  8. For patients who have received only one line of therapy, if the patient has not received autologous stem cell transplantation, the investigator needs to assess as unsuitable or the patient refuses intensive chemotherapy and hematopoietic stem cell transplantation.
  9. Life expectancy ≥ 6 months.
  10. Patients must also meet all of the following criteria to be included in this study:
  11. All patients must provide a signed and dated written informed consent prior to any study-specific procedure, sampling, and analysis.
  12. Patients must be ≥ 18 years of age at the time of informed consent.
  13. ECOG status score of 0 to 2.
  14. Presence of at least one radiologically measurable lesion in 2 perpendicular directions as assessed by CT or MRI and a positive lesion on PET/CT scan consistent with a tumor site identified by CT or MRI.
  15. Adequate bone marrow hematopoietic reserve and organ function.
  16. No uncontrolled medical complications.
  17. Patients should be able to follow the relevant requirements of this study for medication and follow-up.
  18. Willing to comply with contraceptive restrictions.

排除标准:Exclusion Criteria:

  1. Cohort 2, 3:
  2. All patients should not be included in this study if they have any of the following conditions:
  3. Indolent lymphoma-transformed DLBCL, primary mediastinal lymphoma, lymphoma involving the central nervous system, or DLBCL with MYC and BCL2 rearrangements.
  4. Prior use of BTK inhibitors.
  5. Vaccination with live attenuated vaccines or viral vector vaccines within 4 weeks prior to enrollment.
  6. Currently taking vitamin K antagonists, taking 2 or more antiplatelet/anticoagulant drugs at the same time, drugs/herbs or supplements known to potently induce or inhibit CYP3A enzyme activity, proton pump inhibitor drugs, anti-tumor traditional Chinese medicine or failing to meet the protocol-specified withdrawal time before administration in this study.
  7. Major surgery within 4 weeks or anticipated surgery after the start of this study. Or insufficiently recovered from any toxicity and/or complications of previous intervention.
  8. Clinically significant cardiac disorders. History of thrombotic diseases, stroke or intracranial hemorrhage within 6 months.
  9. Active infectious diseases.
  10. Intractable nausea and vomiting that cannot be well controlled by supportive treatment, chronic gastrointestinal diseases, dysphagia, or previous surgical resection of the intestinal segment may affect the adequate absorption of the drug.
  11. The patient has been diagnosed with other malignant diseases other than B-cell lymphoma within the past 2 years.
  12. Patients with hypersensitivity to DZD8586 drug excipients or other chemical analogues.
  13. Patients with severe or uncontrolled systemic diseases, including poorly controlled hypertension and active bleeding constitution.
  14. Serious medical or psychiatric illness that could affect participation in the study or could compromise the ability to consent
  15. Women who are pregnant or breastfeeding.

引自 ClinicalTrials.gov, NCT07059650, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07059650,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07059650